Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 16/20 | 0.67 |
| ▸ | ACE | P12821 | 7/20 | 0.67 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | CSGALNACT1 | Q8TDX6 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9934956 | 1.00 | MME (0.67) | MMEACETAAR1TP53CSGALNACT1 | |
| SCHEMBL9934968 | 1.00 | MME (0.67) | MMEACETAAR1TP53CSGALNACT1 | |
| SCHEMBL9936262 | 0.92 | MME (0.56) | MMEACECSGALNACT1 | |
| SCHEMBL9936258 | 0.92 | MME (0.56) | MMEACECSGALNACT1 | |
| SCHEMBL9934307 | 0.92 | MME (0.54) | MMEACE | |
| SCHEMBL9934316 | 0.92 | MME (0.54) | MMEACE | |
| SCHEMBL9934400 | 0.91 | MME (0.55) | MMEACE | |
| SCHEMBL9934409 | 0.91 | MME (0.55) | MMEACE | |
| SCHEMBL9935014 | 0.90 | MME (0.53) | MMEACETAAR1CSGALNACT1 | |
| SCHEMBL9934754 | 0.90 | MME (0.53) | MMEACECSGALNACT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210032250-A1 | GLUCURONIDE PRODRUGS OF JANUS KINASE INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2021-02-04 | — | — | US | disclosed |
| US-10745405-B2 | Glucuronide prodrugs of Janus kinase inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2020-08-18 | — | — | US | disclosed |
| EP-3609899-A1 | GLUCURONIDE PRODRUGS OF JANUS KINASE INHIBITORS | Theravance Biopharma R&D IP, LLC (US) | 2020-02-19 | — | — | EP | disclosed |
| US-10472366-B2 | Glucuronide prodrugs of tofacitinib | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2019-11-12 | — | — | US | disclosed |
| US-20180339990-A1 | GLUCURONIDE PRODRUGS OF JANUS KINASE INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2018-11-29 | — | — | US | disclosed |
| WO-2018217700-A1 | GLUCURONIDE PRODRUGS OF JANUS KINASE INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2018-11-29 | — | — | WO | disclosed |
| US-20180258094-A1 | GLUCURONIDE PRODRUGS OF TOFACITINIB | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2018-09-13 | — | — | US | disclosed |
| US-9981999-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2018-05-29 | — | — | US | disclosed |
| US-9981999-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2018-05-29 | — | — | US | disclosed |
| US-9873696-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2018-01-23 | — | — | US | disclosed |
| US-20140011997-A1 | NEPRILYSIN INHIBITORS | THERAVANCE, INC. (US) | 2014-01-09 | — | — | US | disclosed |
| US-20140011997-A1 | NEPRILYSIN INHIBITORS | THERAVANCE, INC. (US) | 2014-01-09 | — | — | US | disclosed |
| US-8563512-B2 | Neprilysin inhibitors | THERAVANCE, INC. (US) | 2013-10-22 | — | — | US | disclosed |
| US-8563512-B2 | Neprilysin inhibitors | THERAVANCE, INC. (US) | 2013-10-22 | — | — | US | disclosed |
| US-8563512-B2 | Neprilysin inhibitors | THERAVANCE, INC. (US) | 2013-10-22 | — | — | US | disclosed |
| US-20130259897-A1 | CRYSTALLINE FORMS OF (R)-3-[N-(3'-CHLOROBIPHENYL-4-YLMETHYL)-N'-(3-HYDROXYISOXAZOLE-5-CARBONYL)HYDRAZINO]-2-HYDROXYPROPIONIC ACID ISOPROPYL ESTER | THERAVANCE BIOPHARMA R&D IP, LLC | 2013-10-03 | — | — | US | disclosed |
| US-20120157386-A1 | NEPRILYSIN INHIBITORS | THERAVANCE, INC. (US) | 2012-06-21 | — | — | US | disclosed |
| US-20120157386-A1 | NEPRILYSIN INHIBITORS | THERAVANCE, INC. (US) | 2012-06-21 | — | — | US | disclosed |
| US-20120157386-A1 | NEPRILYSIN INHIBITORS | THERAVANCE, INC. (US) | 2012-06-21 | — | — | US | disclosed |
| WO-2012082857-A1 | NEPRILYSIN INHIBITORS | THERAVANCE, INC. (US) | 2012-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140011997-A1 | NEPRILYSIN INHIBITORS | MME, REN, ACE | MME 1/4885ACE 3/4885TAAR1 317/4885 |
| US-20180258094-A1 | GLUCURONIDE PRODRUGS OF TOFACITINIB | UGT1A1, JAK1, UGT1A3 | MME 4059/4885ACE 2560/4885TAAR1 1570/4885 |
| US-20130259897-A1 | CRYSTALLINE FORMS OF (R)-3-[N-(3'-CHLOROBIPHENYL-4-YLMETHYL)-N'-(3-HYDROXYISOXAZOLE-5-CARBONYL)HYDRAZINO]-2-HYDROXYPROPIONIC ACID ISOPROPYL ESTER | HCAR3, HCAR2, HMGCR | MME 646/4885ACE 56/4885TAAR1 4166/4885 |
| US-10472366-B2 | Glucuronide prodrugs of tofacitinib | UGT1A1, JAK1, UGT1A3 | MME 4059/4885ACE 2560/4885TAAR1 1570/4885 |
| US-20120157386-A1 | NEPRILYSIN INHIBITORS | MME, REN, ACE | MME 1/4885ACE 3/4885TAAR1 317/4885 |
| US-20210032250-A1 | GLUCURONIDE PRODRUGS OF JANUS KINASE INHIBITORS | JAK1, UGT1A1, JAK2 | MME 3500/4885ACE 1422/4885TAAR1 1280/4885 |
| US-10745405-B2 | Glucuronide prodrugs of Janus kinase inhibitors | JAK1, UGT1A1, JAK2 | MME 3500/4885ACE 1422/4885TAAR1 1280/4885 |
| US-20180339990-A1 | GLUCURONIDE PRODRUGS OF JANUS KINASE INHIBITORS | JAK1, UGT1A1, JAK2 | MME 3500/4885ACE 1422/4885TAAR1 1280/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.